Minimally Invasive and Novel Therapeutics (MINT) in Foregut Disease 2021

Live Stream - September 9, 2021 - September 11, 2021
Hands on course at the Fairmont Copley Plaza - September 9, 2021

MINIMALLY INVASIVE AND NOVEL THERAPEUTICS (MINT) IN FOREGUT DISEASE 2021

The coordinated care of patients with foregut disease remains challenging. The goal of the MINT Foregut Course, accredited by Harvard Medical School, aims to give clear guidelines to practicing clinicians who manage such patients. This symposium offers an ideal mix of the traditional standard-of-care principles with new, cutting edge information. It explores issues in several areas including medical management, state-of-the art surgical management, endoluminal therapy and pharmacologic management as well as diet/lifestyle management. Multiple learning modalities will be incorporated into the course to engage the learner in the educational process and help them develop new strategies they can apply in their own practice setting.

LEARNING OBJECTIVES
Upon completion of this activity, participants will be able to:

- Apply new knowledge in the management of patients with reflux and swallowing disorders.
- Develop treatment strategies based on current evidence and expert opinion
- Compare and contrast standard-of-care management with cutting-edge treatments

TARGET AUDIENCE
This course is targeted to Primary Care Physicians, Specialty Physicians, Nurses, Nurse Practitioners, Pharmacists, and Physician Assistants. This course may also be of interest to physicians who practice in Gastroenterology, General Surgery, and Thoracic Surgery.

Offered By:
- Massachusetts General Hospital
- Mass General Brigham
- Mass General Brigham Newton-Wellesley Hospital

Earn up to
15.25 AMA PRA Category 1 Credits™